Jack Mann, MD
Pulmonary Disease · Bayside, NYNPI 1376542217
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $641,560 of the $736,028 with a category attached, or 87.2%. 34 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 51.3% of the total. Reporting peaked in 2019 at $181,045 and has fallen 62.7% since, to $67,536 in 2025. Among pulmonary disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,203 payments — averaging $611.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$378K
- GSK$142K
- Mallinckrodt Enterprises LLC$75K
- Boehringer Ingelheim$69K
- Insmed, Inc.$38K
- Mylan Specialty L.p.$18K
- plus $16K from 28 others
Across 127 payments — averaging $1810.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$230K
What the payments were for
- Consulting fees$28,6464%
- Speaking & faculty fees$641,56087%
- Travel & lodging$34,9205%
- Food & beverage$30,4974%
- Education$3660%
- Gifts$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 338 | $377,599 |
| GSK | 188 | $142,349 |
| Mallinckrodt Enterprises LLC | 56 | $74,812 |
| Boehringer Ingelheim | 185 | $68,896 |
| Insmed, Inc. | 77 | $38,004 |
| Mylan Specialty L.p. | 62 | $17,882 |
| Sunovion Pharmaceuticals Inc. | 37 | $11,013 |
| Actelion Pharmaceuticals US, Inc. | 44 | $875 |
| Philips North America LLC | 23 | $513 |
| Grifols USA, LLC | 22 | $506 |
| AstraZeneca | 23 | $477 |
| Sanofi | 13 | $348 |
| Bayer | 14 | $323 |
| Advanced Respiratory, Inc | 13 | $301 |
| Regeneron Healthcare Solutions, Inc. | 13 | $286 |
| Baxter Healthcare | 12 | $275 |
| Verona Pharma, Inc. | 9 | $258 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $254 |
| ANI Pharmaceuticals, Inc. | 11 | $197 |
| Genentech USA, Inc. | 9 | $171 |
| Merck | 6 | $128 |
| Johnson & Johnson | 5 | $87 |
| United Therapeutics Corporation | 9 | $87 |
| Amgen | 5 | $85 |
| Inspire Medical Systems, Inc. | 2 | $52 |
| Shire North American Group Inc | 3 | $50 |
| Viatris Specialty LLC | 3 | $48 |
| Gilead | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Phadia US Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Pfizer | 1 | $14 |
| Circassia Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$446,424
- TRELEGY ELLIPTA$78,343
- Arikayce$34,529
- NUCALA$27,168
- OFEV$25,185
- Yupelri$17,103
- ANORO$12,646
- LONHALA MAGNAIR$10,378
- DreamWear Pillows$111
How this compares
$736,028 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 33 | $420,035 |
| UptraviSelexipag | 14 | $352,247 |
| OpsumitMacitentan | 25 | $310,325 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 316 | $274,430 |
| AdempasRiociguat | 11 | $145,501 |
| Pirfenidone | 24 | $116,360 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 170 | $103,063 |
| TezspireTezepelumab-Ekko | 17 | $71,999 |
| Tadalafil | 27 | $71,078 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 107 | $59,964 |
| Breo ElliptaFluticasone/Vilanterol | 87 | $46,440 |
| EliquisApixaban | 23 | $27,644 |
| JardianceEmpagliflozin | 36 | $26,532 |
| Spiriva RespimatTiotropium Bromide | 31 | $21,729 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $7,651 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $875 | $662,57239 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Jardiance, Spiriva Respimat | $68,896 | $528,260207 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $142,349 | $431,584587 claims |
| BayerAdempas | $323 | $145,50111 claims |
| AstraZenecaTezspire | $477 | $71,99917 claims |
| PfizerEliquis | $14 | $27,64423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Bayside
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Raji AyinlaBronx$673K
- Charles PowellNew York$654K
- Nashat RabadiBuffalo$613K
- Craig ThurmJamaica$604K
- Michael MandelLarchmont$589K
- Sherif El BayadiSyracuse$571K
- Ali El AtatBrooklyn$482K
- Bisher AkilNew York$480K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.